All three sit in the hormone and metabolic optimization space, but they serve different types of patients
In June 2021, the agency approved Wegovy (semaglutide 2.4 mg once weekly) for weight management in adults with a body mass index (BMI) of 30 kg/m or greater (obesity), or a BMI of 27 kg/m or greater (overweight) with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea
High Alt
If youre building a foundational wellness or longevity routine, NAC takes the lead
Good sources are meats like beef, liver, and chicken
Many community posts describe tirzepatides appetite effect as feeling smoother or longer-lasting across the weekly interval, whereas some report a more noticeable tapering with semaglutide toward the end of the week